Does the media refer more to RZLT or STOK?

In the previous week, Rezolute had 21 more articles in the media than Stoke Therapeutics. MarketBeat recorded 23 mentions for Rezolute and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.86 beat Rezolute's score of 0.39 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, RZLT or ABSI?

Rezolute has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$77.59M -$0.76 N/A Absci $2.80M 665.36 -$115.18M -$0.80 N/A

Is RZLT or ABSI more profitable?

Rezolute has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -62.99% -57.94% Absci -7,756.38% -61.71% -54.52%

Does the media favor RZLT or ABSI?

In the previous week, Rezolute had 21 more articles in the media than Absci. MarketBeat recorded 23 mentions for Rezolute and 2 mentions for Absci. Absci's average media sentiment score of 1.25 beat Rezolute's score of 0.39 indicating that Absci is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Absci 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, RZLT or NBTX?

Nanobiotix has higher revenue and earnings than Rezolute. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rezolute N/A N/A -$77.59M -$0.76 N/A Nanobiotix $36.87M 35.42 -$27.11M N/A N/A

Is RZLT or NBTX more profitable?

Nanobiotix's return on equity of 0.00% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -62.99% -57.94% Nanobiotix N/A N/A N/A

Does the media refer more to RZLT or NBTX?

In the previous week, Rezolute had 13 more articles in the media than Nanobiotix. MarketBeat recorded 23 mentions for Rezolute and 10 mentions for Nanobiotix. Rezolute's average media sentiment score of 0.39 beat Nanobiotix's score of -0.20 indicating that Rezolute is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nanobiotix 0 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is RZLT or TSHA more profitable?

Taysha Gene Therapies' return on equity of -56.19% beat Rezolute's return on equity. Company Net Margins Return on Equity Return on Assets Rezolute N/A -62.99% -57.94% Taysha Gene Therapies N/A -56.19% -41.84%

Does the media favor RZLT or TSHA?

In the previous week, Rezolute had 20 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 23 mentions for Rezolute and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.55 beat Rezolute's score of 0.39 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor RZLT or NTLA?

In the previous week, Rezolute had 22 more articles in the media than Intellia Therapeutics. MarketBeat recorded 23 mentions for Rezolute and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.84 beat Rezolute's score of 0.39 indicating that Intellia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rezolute 1 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Intellia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Rezolute (RZLT) Competitors

$4.01 -0.06 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$4.00 0.00 (-0.12%)

As of 07:30 PM Eastern

Compare

RZLT vs. STOK, ABSI, NBTX, TSHA, and NTLA

Should you buy Rezolute stock or one of its competitors? Rezolute's main competitors and comparable companies include Stoke Therapeutics (STOK), Absci (ABSI), Nanobiotix (NBTX), Taysha Gene Therapies (TSHA), and Intellia Therapeutics (NTLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rezolute compare to Stoke Therapeutics?

Rezolute (NASDAQ:RZLT) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

Rezolute has a net margin of 0.00% compared to Stoke Therapeutics' net margin of -753.60%. Stoke Therapeutics' return on equity of -59.36% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
Stoke Therapeutics	-753.60%	-59.36%	-51.46%

Stoke Therapeutics has higher revenue and earnings than Rezolute. Stoke Therapeutics is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
Stoke Therapeutics	$184.42M	9.08	-$6.89M	-$3.34	N/A

83.0% of Rezolute shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 9.6% of Stoke Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Rezolute has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Stoke Therapeutics has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Rezolute currently has a consensus price target of $10.44, indicating a potential upside of 158.85%. Stoke Therapeutics has a consensus price target of $44.25, indicating a potential upside of 70.55%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Stoke Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Stoke Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

In the previous week, Rezolute had 21 more articles in the media than Stoke Therapeutics. MarketBeat recorded 23 mentions for Rezolute and 2 mentions for Stoke Therapeutics. Stoke Therapeutics' average media sentiment score of 0.86 beat Rezolute's score of 0.39 indicating that Stoke Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stoke Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rezolute beats Stoke Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rezolute compare to Absci?

Rezolute (NASDAQ:RZLT) and Absci (NASDAQ:ABSI) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Rezolute had 21 more articles in the media than Absci. MarketBeat recorded 23 mentions for Rezolute and 2 mentions for Absci. Absci's average media sentiment score of 1.25 beat Rezolute's score of 0.39 indicating that Absci is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Absci	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute currently has a consensus target price of $10.44, indicating a potential upside of 158.85%. Absci has a consensus target price of $13.71, indicating a potential upside of 26.33%. Given Rezolute's higher possible upside, analysts plainly believe Rezolute is more favorable than Absci.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Absci	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

Rezolute has a net margin of 0.00% compared to Absci's net margin of -7,756.38%. Absci's return on equity of -61.71% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
Absci	-7,756.38%	-61.71%	-54.52%

Rezolute has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market. Comparatively, Absci has a beta of 2.27, meaning that its stock price is 127% more volatile than the broader market.

Rezolute has higher earnings, but lower revenue than Absci. Absci is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
Absci	$2.80M	665.36	-$115.18M	-$0.80	N/A

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 52.1% of Absci shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 10.5% of Absci shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rezolute beats Absci on 9 of the 15 factors compared between the two stocks.

How does Rezolute compare to Nanobiotix?

Rezolute (NASDAQ:RZLT) and Nanobiotix (NASDAQ:NBTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

Rezolute currently has a consensus target price of $10.44, suggesting a potential upside of 158.85%. Nanobiotix has a consensus target price of $46.67, suggesting a potential upside of 80.88%. Given Rezolute's stronger consensus rating and higher probable upside, equities research analysts clearly believe Rezolute is more favorable than Nanobiotix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Nanobiotix	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Rezolute had 13 more articles in the media than Nanobiotix. MarketBeat recorded 23 mentions for Rezolute and 10 mentions for Nanobiotix. Rezolute's average media sentiment score of 0.39 beat Nanobiotix's score of -0.20 indicating that Rezolute is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nanobiotix	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Nanobiotix's return on equity of 0.00% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
Nanobiotix	N/A	N/A	N/A

Rezolute has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market. Comparatively, Nanobiotix has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Nanobiotix has higher revenue and earnings than Rezolute.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
Nanobiotix	$36.87M	35.42	-$27.11M	N/A	N/A

83.0% of Rezolute shares are held by institutional investors. Comparatively, 38.8% of Nanobiotix shares are held by institutional investors. 14.8% of Rezolute shares are held by insiders. Comparatively, 3.5% of Nanobiotix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Rezolute beats Nanobiotix on 7 of the 12 factors compared between the two stocks.

How does Rezolute compare to Taysha Gene Therapies?

Rezolute (NASDAQ:RZLT) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 14.8% of Rezolute shares are owned by insiders. Comparatively, 3.5% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Rezolute had 20 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 23 mentions for Rezolute and 3 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.55 beat Rezolute's score of 0.39 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rezolute has higher earnings, but lower revenue than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Rezolute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
Taysha Gene Therapies	$9.77M	157.58	-$109M	-$0.42	N/A

Rezolute presently has a consensus price target of $10.44, suggesting a potential upside of 158.85%. Taysha Gene Therapies has a consensus price target of $12.77, suggesting a potential upside of 170.25%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Rezolute has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its share price is 19% more volatile than the broader market.

Taysha Gene Therapies' return on equity of -56.19% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
Taysha Gene Therapies	N/A	-56.19%	-41.84%

Summary

Taysha Gene Therapies beats Rezolute on 10 of the 15 factors compared between the two stocks.

How does Rezolute compare to Intellia Therapeutics?

Rezolute (NASDAQ:RZLT) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability.

In the previous week, Rezolute had 22 more articles in the media than Intellia Therapeutics. MarketBeat recorded 23 mentions for Rezolute and 1 mentions for Intellia Therapeutics. Intellia Therapeutics' average media sentiment score of 1.84 beat Rezolute's score of 0.39 indicating that Intellia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rezolute	1 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Intellia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

83.0% of Rezolute shares are owned by institutional investors. Comparatively, 88.8% of Intellia Therapeutics shares are owned by institutional investors. 14.8% of Rezolute shares are owned by company insiders. Comparatively, 3.5% of Intellia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Rezolute has higher earnings, but lower revenue than Intellia Therapeutics. Rezolute is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rezolute	N/A	N/A	-$77.59M	-$0.76	N/A
Intellia Therapeutics	$67.67M	25.23	-$412.69M	-$3.36	N/A

Rezolute has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -672.16%. Intellia Therapeutics' return on equity of -57.79% beat Rezolute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rezolute	N/A	-62.99%	-57.94%
Intellia Therapeutics	-672.16%	-57.79%	-47.29%

Rezolute has a beta of 0.54, suggesting that its stock price is 46% less volatile than the broader market. Comparatively, Intellia Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Rezolute currently has a consensus target price of $10.44, suggesting a potential upside of 158.85%. Intellia Therapeutics has a consensus target price of $20.98, suggesting a potential upside of 72.16%. Given Rezolute's stronger consensus rating and higher probable upside, equities research analysts plainly believe Rezolute is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rezolute	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Intellia Therapeutics	4 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.35

Summary

Rezolute and Intellia Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Rezolute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RZLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RZLT vs. The Competition

Export

Metric	Rezolute	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$387.85M	$3.84B	$7.09B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-5.28	12.99	274.61	26.05
Price / Sales	N/A	1,288.54	600.52	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	3.82	16.63	10.92	6.31
Net Income	-$77.59M	-$22.67M	$3.50B	$361.43M
7 Day Performance	2.82%	-3.05%	-2.11%	-1.67%
1 Month Performance	-12.06%	-10.75%	-6.34%	-3.94%
1 Year Performance	-56.37%	21.11%	8.81%	2.77%

Rezolute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RZLT Rezolute	3.1916 of 5 stars	$4.01 -1.5%	$10.44 +160.5%	-56.8%	$387.85M	N/A	N/A	71	Analyst Upgrade Analyst Revision
STOK Stoke Therapeutics	3.0759 of 5 stars	$25.68 +0.7%	$44.25 +72.3%	+10.3%	$1.67B	$184.42M	N/A	170
ABSI Absci	2.7043 of 5 stars	$9.89 +4.2%	$13.71 +38.7%	+243.5%	$1.65B	$2.80M	N/A	140
NBTX Nanobiotix	2.4272 of 5 stars	$32.05 -1.7%	$46.67 +45.6%	+48.9%	$1.64B	$36.87M	N/A	97	News Coverage Analyst Revision
TSHA Taysha Gene Therapies	2.5614 of 5 stars	$4.87 -2.3%	$12.77 +162.0%	+49.1%	$1.61B	$9.77M	N/A	99	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RZLT) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rezolute (RZLT) Competitors

RZLT vs. STOK, ABSI, NBTX, TSHA, and NTLA

How does Rezolute compare to Stoke Therapeutics?

Summary

How does Rezolute compare to Absci?

Summary

How does Rezolute compare to Nanobiotix?

Summary

How does Rezolute compare to Taysha Gene Therapies?

Summary

How does Rezolute compare to Intellia Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rezolute (RZLT) Competitors

RZLT vs. STOK, ABSI, NBTX, TSHA, and NTLA

How does Rezolute compare to Stoke Therapeutics?

Is RZLT or STOK more profitable?

Which has preferable earnings and valuation, RZLT or STOK?

Do institutionals and insiders believe in RZLT or STOK?

Which has more risk and volatility, RZLT or STOK?

Do analysts rate RZLT or STOK?

Does the media refer more to RZLT or STOK?

Summary

How does Rezolute compare to Absci?

Does the media favor RZLT or ABSI?

Do analysts recommend RZLT or ABSI?

Is RZLT or ABSI more profitable?

Which has more risk and volatility, RZLT or ABSI?

Which has stronger earnings and valuation, RZLT or ABSI?

Do institutionals and insiders believe in RZLT or ABSI?

Summary

How does Rezolute compare to Nanobiotix?

Do analysts recommend RZLT or NBTX?

Does the media refer more to RZLT or NBTX?

Is RZLT or NBTX more profitable?

Which has more volatility & risk, RZLT or NBTX?

Which has preferable valuation and earnings, RZLT or NBTX?

Do institutionals and insiders hold more shares of RZLT or NBTX?

Summary

How does Rezolute compare to Taysha Gene Therapies?

Do institutionals and insiders have more ownership in RZLT or TSHA?

Does the media favor RZLT or TSHA?

Which has stronger earnings & valuation, RZLT or TSHA?

Do analysts prefer RZLT or TSHA?

Which has more risk & volatility, RZLT or TSHA?

Is RZLT or TSHA more profitable?

Summary

How does Rezolute compare to Intellia Therapeutics?

Does the media favor RZLT or NTLA?

Do insiders and institutionals have more ownership in RZLT or NTLA?

Which has better valuation & earnings, RZLT or NTLA?

Is RZLT or NTLA more profitable?

Which has more risk and volatility, RZLT or NTLA?

Do analysts prefer RZLT or NTLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RZLT vs. The Competition

Rezolute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools